Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents

[1]  A. Haas,et al.  Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[2]  R. Deshaies,et al.  Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases. , 2017, Nature chemical biology.

[3]  Seth M. Cohen,et al.  Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. , 2017, Nature chemical biology.

[4]  Lanhai Lü,et al.  USP14 inhibitor attenuates cerebral ischemia/reperfusion‐induced neuronal injury in mice , 2017, Journal of neurochemistry.

[5]  Jinbao Liu,et al.  Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor , 2017, Cell Death & Disease.

[6]  D. Zang,et al.  Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases , 2017, Oncotarget.

[7]  Xiaohong Xu,et al.  The role of ubiquitin‐specific protease 14 (USP14) in cell adhesion‐mediated drug resistance (CAM‐DR) of multiple myeloma cells , 2017, European journal of haematology.

[8]  D. Zang,et al.  Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms , 2016, Journal of Hematology & Oncology.

[9]  D. Zang,et al.  A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy , 2016, Oncogene.

[10]  Jing-jing Wu,et al.  Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma. , 2016, The international journal of biochemistry & cell biology.

[11]  D. Zang,et al.  Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy , 2016, Biochemical pharmacology.

[12]  S. Pierrou,et al.  The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells , 2016, Scientific Reports.

[13]  Qiang Li,et al.  Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer , 2016, Cellular Physiology and Biochemistry.

[14]  D. Chauhan,et al.  Targeting 19S-Proteasome Deubiquitinase Rpn11/POH1/PSMD14 in Multiple Myeloma , 2015 .

[15]  D. Zang,et al.  Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo , 2015, Oncotarget.

[16]  J. Weissman,et al.  Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. , 2015, Cancer cell.

[17]  Junying Yuan,et al.  Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system , 2015, eLife.

[18]  A. Chanan-Khan,et al.  Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b‐AP15 , 2015, Chemical biology & drug design.

[19]  S. Wesselborg,et al.  Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagy , 2015, Autophagy.

[20]  T. Liang,et al.  WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. , 2015, Cancer letters.

[21]  Jinbao Liu,et al.  Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds , 2015, Oncoscience.

[22]  S. Linder,et al.  Deubiquitinase inhibition as a cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.

[23]  Christine Roder,et al.  Auranofin: Repurposing an Old Drug for a Golden New Age , 2015, Drugs in R&D.

[24]  S. Linder,et al.  Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. , 2014, Antioxidants & redox signaling.

[25]  Jinbao Liu,et al.  Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells. , 2014, Cancer cell & microenvironment.

[26]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[27]  Quentin Liu,et al.  Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms , 2014, Oncotarget.

[28]  Ping Zhou,et al.  Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth , 2014, Oncotarget.

[29]  Q. Dou,et al.  A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases , 2014, Scientific Reports.

[30]  Elias S. J. Arnér,et al.  The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death , 2014, Molecular Pharmacology.

[31]  J. Byrd,et al.  Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. , 2014, Cancer research.

[32]  B. Aggarwal,et al.  Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. , 2014, Current medicinal chemistry.

[33]  R. Roden,et al.  Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses , 2014, Clinical Cancer Research.

[34]  Chris Orvig,et al.  Metallodrugs in medicinal inorganic chemistry. , 2014, Chemical reviews.

[35]  Q. Dou,et al.  Gold(III)-Dithiocarbamato Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia , 2014, PloS one.

[36]  Q. Dou,et al.  Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation , 2013, Clinical Cancer Research.

[37]  M. Huang,et al.  Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells , 2013, Molecular Cancer Therapeutics.

[38]  D. Finley,et al.  Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling , 2013, Oncogenesis.

[39]  J. Guh,et al.  Ubiquitin C-terminal hydrolase-L5 is required for high glucose-induced transforming growth factor-β receptor I expression and hypertrophy in mesangial cells. , 2013, Archives of biochemistry and biophysics.

[40]  P. Sadler,et al.  Challenges for metals in medicine: how nanotechnology may help to shape the future. , 2013, ACS nano.

[41]  Qiang Li,et al.  Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin , 2013, International journal of molecular sciences.

[42]  Jun Du,et al.  Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analog AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells , 2013, Molecular Cancer Therapeutics.

[43]  C. Che,et al.  Deubiquitinases as potential anti-cancer targets for gold(III) complexes. , 2013, Chemical communications.

[44]  Yutong Zhao,et al.  Overexpression of USP14 Protease Reduces I-κB Protein Levels and Increases Cytokine Release in Lung Epithelial Cells* , 2013, The Journal of Biological Chemistry.

[45]  Duan Ma,et al.  Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. , 2013, Biochimica et biophysica acta.

[46]  Michael Groessl,et al.  Anticancer metallodrug research analytically painting the “omics” picture—current developments and future trends , 2013, Analytical and Bioanalytical Chemistry.

[47]  J. Yap,et al.  The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition , 2012, BMC Cancer.

[48]  S. Linder,et al.  Proteasome deubiquitinases as novel targets for cancer therapy. , 2012, The international journal of biochemistry & cell biology.

[49]  Jennifer A. Watson,et al.  Usp14 Deficiency Increases Tau Phosphorylation without Altering Tau Degradation or Causing Tau-Dependent Deficits , 2012, PloS one.

[50]  Q. Dou,et al.  1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity , 2012, JBIC Journal of Biological Inorganic Chemistry.

[51]  B. Cvek,et al.  Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. , 2012, Mini reviews in medicinal chemistry.

[52]  Parantu K. Shah,et al.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.

[53]  V. Quesada,et al.  Deubiquitinases in cancer: new functions and therapeutic options , 2012, Oncogene.

[54]  A. Amerik,et al.  Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes , 2012, Cell cycle.

[55]  V. Battaglia,et al.  Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. , 2012, Chemistry & biology.

[56]  F. Formaggio,et al.  Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics. , 2012, Journal of medicinal chemistry.

[57]  A. DeCaprio,et al.  Application of the Hard and Soft, Acids and Bases (HSAB) theory to toxicant--target interactions. , 2012, Chemical research in toxicology.

[58]  A. Levitzki,et al.  A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. , 2011, Cellular signalling.

[59]  Mårten Fryknäs,et al.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.

[60]  A. Jadhav,et al.  Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. , 2011, Chemistry & biology.

[61]  M. Mattern,et al.  Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. , 2011, Assay and drug development technologies.

[62]  Seth M. Cohen,et al.  Emerging trends in metalloprotein inhibition. , 2011, Dalton transactions.

[63]  N. Donato,et al.  Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. , 2011, Blood.

[64]  X. Niu,et al.  Effect of ubiquitin carboxy‐terminal hydrolase 37 on apoptotic in A549 cells , 2011, Cell biochemistry and function.

[65]  Muzamil Ahmad,et al.  Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury , 2011, Neurobiology of Disease.

[66]  J. V. Van Drie.  Protein folding, protein homeostasis, and cancer , 2011, Chinese journal of cancer.

[67]  N. Donato,et al.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.

[68]  Min Jae Lee,et al.  Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes* , 2010, Molecular & Cellular Proteomics.

[69]  W. Bornmann,et al.  Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications , 2010, Molecular Cancer Therapeutics.

[70]  Min Jae Lee,et al.  Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.

[71]  E. Andreu,et al.  Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells , 2010, Oncogene.

[72]  J. Rain,et al.  Synthesis and Biological Evaluation of 9‐Oxo‐9H‐indeno[1,2‐b]pyrazine‐2,3‐dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes , 2010, ChemMedChem.

[73]  M. Červinka,et al.  Zinc pyrithione induces cellular stress signaling and apoptosis in Hep-2 cervical tumor cells: the role of mitochondria and lysosomes , 2010, BioMetals.

[74]  Ying Sun,et al.  Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells , 2010, JBIC Journal of Biological Inorganic Chemistry.

[75]  K. Thomas,et al.  The environmental fate and effects of antifouling paint biocides , 2010, Biofouling.

[76]  U. Jaehde,et al.  Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. , 2009, Journal of inorganic biochemistry.

[77]  Carlos Sanchez‐Cano,et al.  Novel and emerging approaches for the delivery of metallo-drugs. , 2009, Dalton transactions.

[78]  J. Rain,et al.  Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells , 2009, Molecular Cancer Therapeutics.

[79]  C. Isella,et al.  The Thioxotriazole Copper(II) Complex A0 Induces Endoplasmic Reticulum Stress and Paraptotic Death in Human Cancer Cells* , 2009, The Journal of Biological Chemistry.

[80]  Q. Dou,et al.  The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. , 2009, Coordination chemistry reviews.

[81]  H. Harino,et al.  Inhibition of acetylcholinesterase by metabolites of copper pyrithione (CuPT) and its possible involvement in vertebral deformity of a CuPT-exposed marine teleostean fish. , 2009, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[82]  Di Chen,et al.  Metal complexes, their cellular targets and potential for cancer therapy. , 2009, Current pharmaceutical design.

[83]  Q. Dou,et al.  Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. , 2008, Journal of medicinal chemistry.

[84]  Sanjeev Banerjee,et al.  Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. , 2008, Cancer research.

[85]  J. Hacia,et al.  Synthesis and anticancer properties of water-soluble zinc ionophores. , 2008, Cancer research.

[86]  P. Sadler,et al.  New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.

[87]  F. Colland,et al.  Targeting ubiquitin specific proteases for drug discovery. , 2008, Biochimie.

[88]  Xiaohua Li,et al.  Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. , 2007, Molecular biology of the cell.

[89]  H. Ploegh,et al.  Mechanisms, biology and inhibitors of deubiquitinating enzymes. , 2007, Nature chemical biology.

[90]  T. Butt,et al.  Deubiquitinating enzymes as novel anticancer targets. , 2007, Future oncology.

[91]  V. Gandin,et al.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.

[92]  F. Sarkar,et al.  Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. , 2007, Cancer research.

[93]  M. Rolfe,et al.  The JAMM motif of human deubiquitinase Poh1 is essential for cell viability , 2007, Molecular Cancer Therapeutics.

[94]  A. Goldberg,et al.  hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37 , 2006, The EMBO journal.

[95]  F. Sarkar,et al.  Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. , 2006, Journal of medicinal chemistry.

[96]  Di Chen,et al.  A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. , 2006, Cancer research.

[97]  Q Ping Dou,et al.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.

[98]  P. Ribeiro,et al.  The 19 S Proteasomal Subunit POH1 Contributes to the Regulation of c-Jun Ubiquitination, Stability, and Subcellular Localization* , 2006, Journal of Biological Chemistry.

[99]  A. Singh,et al.  Multiple biological activities of curcumin: a short review. , 2006, Life sciences.

[100]  P. Dijke,et al.  The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-β signalling , 2005, Oncogene.

[101]  Di Chen,et al.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells , 2005, Breast Cancer Research.

[102]  L. Seal,et al.  Zinc pyrithione in alcohol-based products for skin antisepsis: Persistence of antimicrobial effects , 2005, American Journal of Infection Control.

[103]  R. Hartmann-Petersen,et al.  Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast. , 2004, Journal of molecular biology.

[104]  M. Figueiredo-Pereira,et al.  Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. , 2004, Biochemical and biophysical research communications.

[105]  S. Fang,et al.  A field guide to ubiquitylation. , 2004, Cellular and molecular life sciences : CMLS.

[106]  S. Fang,et al.  Ubiquitin-proteasome system , 2004, Cellular and Molecular Life Sciences CMLS.

[107]  N. Nukina,et al.  Inhibition of Proteasomal Function by Curcumin Induces Apoptosis through Mitochondrial Pathway* , 2004, Journal of Biological Chemistry.

[108]  W. Guida,et al.  Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. , 2004, Biochemical pharmacology.

[109]  Peter T Lansbury,et al.  Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. , 2003, Chemistry & biology.

[110]  K. To,et al.  Platinum‐based anticancer agents: Innovative design strategies and biological perspectives , 2003, Medicinal research reviews.

[111]  Phoebe E. Bailey,et al.  A double‐blind randomized vehicle‐controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity , 2003, International journal of cosmetic science.

[112]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.

[113]  Muyang Li,et al.  Crystal Structure of a UBP-Family Deubiquitinating Enzyme in Isolation and in Complex with Ubiquitin Aldehyde , 2002, Cell.

[114]  G. Piérard,et al.  A Multicenter Randomized Trial of Ketoconazole 2% and Zinc Pyrithione 1% Shampoos in Severe Dandruff and Seborrheic Dermatitis , 2002, Skin Pharmacology and Physiology.

[115]  V. Spataro,et al.  The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells. , 2002, Anticancer research.

[116]  T. Yao,et al.  A cryptic protease couples deubiquitination and degradation by the proteasome , 2002, Nature.

[117]  H. Ploegh,et al.  Multiple associated proteins regulate proteasome structure and function. , 2002, Molecular cell.

[118]  S. Merajver,et al.  Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. , 2002, Cancer research.

[119]  L. Aravind,et al.  Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26S Proteasome , 2002, Science.

[120]  F. Fitzpatrick,et al.  Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. , 2002, Molecular pharmacology.

[121]  H. Ploegh,et al.  A novel active site‐directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14 , 2001, The EMBO journal.

[122]  J. Melo,et al.  BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. , 2000, Cancer research.

[123]  M. Bolotin-Fukuhara,et al.  A mutation in a novel yeast proteasomal gene, RPN11/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology. , 1998, Molecular biology of the cell.

[124]  G. Hu.  Copper stimulates proliferation of human endothelial cells under culture , 1998, Journal of cellular biochemistry.

[125]  Wei Xu,et al.  Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome , 1997, Nature.

[126]  D. Wolf,et al.  Proteasomes: destruction as a programme. , 1996, Trends in biochemical sciences.

[127]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[128]  S L Rizk,et al.  Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. , 1984, Cancer research.

[129]  P. Gullino,et al.  Ceruloplasmin, copper ions, and angiogenesis. , 1982, Journal of the National Cancer Institute.

[130]  A. Lorber,et al.  Inhibitory effects of a new oral gold compound on hela cells , 1979, Cancer.

[131]  L. Hamilton,et al.  Biochemical significance of the hard and soft acids and bases principle. , 1978, Chemico-biological interactions.

[132]  C. Nowell.  The minute chromosome (Ph1) in chronic granulocytic leukemia , 1962, Blut: Zeitschrift für die Gesamte Blutforschung.

[133]  Shusen Zheng,et al.  WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. , 2017, American journal of translational research.

[134]  C. Che,et al.  Chemical Biology of Anticancer Gold(III) and Gold(I) Complexes , 2016 .

[135]  Yingying Wang,et al.  Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer , 2014, Medical Oncology.

[136]  P. Richardson,et al.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. , 2014, Blood.

[137]  Q. Dou,et al.  New applications of old metal-binding drugs in the treatment of human cancer. , 2012, Frontiers in bioscience.

[138]  H. Amano,et al.  Toxicity and metabolism of copper pyrithione and its degradation product, 2,2'-dipyridyldisulfide in a marine polychaete. , 2011, Chemosphere.

[139]  T. O'Brien,et al.  Therapeutic strategies within the ubiquitin proteasome system , 2010, Cell Death and Differentiation.

[140]  N. Shah.  Loss of response to imatinib: mechanisms and management. , 2005, Hematology. American Society of Hematology. Education Program.

[141]  H. Kantarjian,et al.  The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. , 2003, Haematologica.

[142]  V. Bhat,et al.  Copper and ceruloplasmin status in serum of prostate and colon cancer patients. , 2003, Indian journal of physiology and pharmacology.

[143]  J. Balibrea,et al.  Serum and tissue trace metal levels in lung cancer. , 1989, Oncology.

[144]  P. Nowell.  The minute chromosome (Phl) in chronic granulocytic leukemia. , 1962, Blut.